Guest Contributor

Canada's biopharm R&D policy needs revamping

Guest Contributor
July 30, 2013

Analysis

By Jorge Niosi

The picture of our pharmaceutical industry is not rosy. According to the Patented Medicine Prices Review Board, Canada's pharmaceutical expenditures on R&D have declined by over 30% since a high in 2008 to 2011.

... Please become a Member or login to read the rest of this article ...


Other stories mentioning these organizations, people and topics

Other News

Cabinet shuffle delivers status quo for S&T

Canadian firms must take a global approach to managing, implementing innovation

CNBC moves back to AECL amidst changing mandates of research organizations

Angel investment data improve with release of third survey results






Events For Leaders in
Science, Tech, Innovation, and Policy


Discuss and learn from those in the know at our virtual and in-person events.



See Upcoming Events










You have 0 free articles remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in






Top

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.